CN108472381B - 化合物及其治疗用途 - Google Patents

化合物及其治疗用途 Download PDF

Info

Publication number
CN108472381B
CN108472381B CN201680071566.0A CN201680071566A CN108472381B CN 108472381 B CN108472381 B CN 108472381B CN 201680071566 A CN201680071566 A CN 201680071566A CN 108472381 B CN108472381 B CN 108472381B
Authority
CN
China
Prior art keywords
preparation
compound
oxy
acid
hydroxymethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680071566.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN108472381A (zh
Inventor
C·皮克福德
C·沃森
M·格洛索普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centauri Therapeutics Ltd
Original Assignee
Centauri Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centauri Therapeutics Ltd filed Critical Centauri Therapeutics Ltd
Publication of CN108472381A publication Critical patent/CN108472381A/zh
Application granted granted Critical
Publication of CN108472381B publication Critical patent/CN108472381B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Air Filters, Heat-Exchange Apparatuses, And Housings Of Air-Conditioning Units (AREA)
  • Central Air Conditioning (AREA)
CN201680071566.0A 2015-10-08 2016-10-07 化合物及其治疗用途 Active CN108472381B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1517859.3 2015-10-08
GBGB1517859.3A GB201517859D0 (en) 2015-10-08 2015-10-08 Novel compounds and therapeutic uses thereof
PCT/GB2016/053134 WO2017060729A1 (en) 2015-10-08 2016-10-07 Compounds and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
CN108472381A CN108472381A (zh) 2018-08-31
CN108472381B true CN108472381B (zh) 2023-06-06

Family

ID=55130801

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680071566.0A Active CN108472381B (zh) 2015-10-08 2016-10-07 化合物及其治疗用途

Country Status (9)

Country Link
US (2) US10953100B2 (https=)
EP (1) EP3359201A1 (https=)
JP (1) JP7065775B2 (https=)
CN (1) CN108472381B (https=)
AU (1) AU2016335365B2 (https=)
GB (1) GB201517859D0 (https=)
IL (1) IL258511B (https=)
WO (2) WO2017060728A1 (https=)
ZA (1) ZA201802256B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019002879A (es) 2016-09-13 2019-09-18 Centauri Therapeutics Ltd Compuestos novedosos y usos terapeuticos de los mismos.
GB201707076D0 (en) * 2017-05-04 2017-06-21 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB201705686D0 (en) * 2017-04-07 2017-05-24 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB201705684D0 (en) * 2017-04-07 2017-05-24 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB201707079D0 (en) 2017-05-04 2017-06-21 Centauri Therapeutics Ltd Novel compounds and therapeutics uses thereof
GB201816554D0 (en) * 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
CN111748089B (zh) * 2019-03-28 2023-07-18 成都先导药物开发股份有限公司 一种生物素标记化合物以及确定化合物结合靶标蛋白的方法
CN116535449B (zh) * 2023-03-22 2025-09-16 华东理工大学 一种糖基没食子酸类衍生物及其制备方法与在制备乳腺癌靶向诊疗材料中的应用
GB202406865D0 (en) 2024-05-15 2024-06-26 Centauri Therapeutics Ltd Novel compounds and therapeutics uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101360728A (zh) * 2005-10-25 2009-02-04 艾吉拉医疗股份有限公司 Iap bir结构域结合化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6172045B1 (en) 1994-12-07 2001-01-09 Neorx Corporation Cluster clearing agents
US7645743B2 (en) 1999-12-22 2010-01-12 Altermune, Llc Chemically programmable immunity
EP2322209A3 (en) 2002-08-20 2012-02-01 Glykos Finland Oy Tumor specific oligosaccharide epitopes and use thereof
JP4430344B2 (ja) * 2002-09-09 2010-03-10 独立行政法人科学技術振興機構 多岐用途型リンカー化合物及びリガンド、並びにそれらの製造方法
EP1653977A2 (en) 2003-07-17 2006-05-10 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Treatment of disorders associated with natural killer t cells
US7998486B2 (en) 2006-10-25 2011-08-16 Newlink Genetics Corporation Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes
CN102459298A (zh) * 2009-05-05 2012-05-16 阿尔特姆恩科技责任有限公司 化学可编程免疫
US9636419B2 (en) * 2013-10-11 2017-05-02 The Universit of Kansas Targeting multiple receptors on a cell surface for specific cell targeting
GB201411150D0 (en) * 2014-06-23 2014-08-06 Altermune Technologies Llc Novel aptamers and therapeutic uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101360728A (zh) * 2005-10-25 2009-02-04 艾吉拉医疗股份有限公司 Iap bir结构域结合化合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Highly Stable Aptamers Selected from a 2′-Fully Modified fGmH RNA Library for Targeting Biomaterials;Adam D. Friedman 等;《Biomaterials》;20160101;第36卷;摘要、图3 *
Phthalimide conjugation as a strategy for in vivo target protein degradation;Georg E. Winter 等;《SCIENCE》;20150619;第348卷(第6421期);图2C *
Retargeting pre-existing human antibodies to a bacterial pathogen with an alpha-Gal conjugated aptamer;Sascha A. Kristian1 等;《JOURNAL OF MOLECULAR MEDICINE》;20150505;第93卷(第6期);摘要 *

Also Published As

Publication number Publication date
AU2016335365B2 (en) 2021-12-09
US20210369850A1 (en) 2021-12-02
AU2016335365A1 (en) 2018-04-26
CA3001084A1 (en) 2017-04-13
WO2017060729A1 (en) 2017-04-13
WO2017060728A1 (en) 2017-04-13
US10953100B2 (en) 2021-03-23
JP2018531287A (ja) 2018-10-25
EP3359201A1 (en) 2018-08-15
CN108472381A (zh) 2018-08-31
IL258511A (en) 2018-06-28
GB201517859D0 (en) 2015-11-25
ZA201802256B (en) 2019-01-30
US20180280521A1 (en) 2018-10-04
JP7065775B2 (ja) 2022-05-12
IL258511B (en) 2021-10-31
NZ741118A (en) 2024-07-26

Similar Documents

Publication Publication Date Title
CN108472381B (zh) 化合物及其治疗用途
JP2018531287A6 (ja) 化合物及びそれらの治療用途
US9375434B2 (en) Antitumor effect potentiator composed of imidazooxazine compound
KR102544465B1 (ko) 신규 화합물 및 그의 치료 용도
TWI904095B (zh) 乙醯輔酶a合成酶短鏈2(acss2)之小分子抑制劑
EP3619223A1 (en) Compounds and therapeutic uses thereof
KR102871984B1 (ko) 화합물 및 그의 치료 용도
AU2006222232A1 (en) 3,4,5-substituted piperidine compounds
US20230149551A1 (en) Arginine methyltransferase 5 (prmt5) degraders and uses thereof
TW201843161A (zh) 作為抗菌劑之三環2-喹啉酮
EP3606558B1 (en) Novel compounds and therapeutic uses thereof
CN118255716A (zh) 一种新型具有抗菌和抗癌功能的苯基喹诺酮类化合物及其制备
KR20250137136A (ko) 항균 및 항암 기능을 갖는 신규 페닐퀴놀론 화합물, 및 이의 제조
CA3001084C (en) Aptamer or biotin conjugates for the treatment of cancer or infectious diseases
US12065429B2 (en) Small molecule modulators of IL-17
CA3036405C (en) Novel compounds and therapeutic uses thereof
HK40084694A (en) Azalactam compounds as hpk1 inhibitors
HK40100661A (zh) 作为enpp1和cdnp抑制剂的膦酸盐
HK40011971A (en) Peptide compounds and therapeutic uses thereof
HK40011971B (en) Peptide compounds and therapeutic uses thereof
EA038112B1 (ru) Новые соединения и их терапевтические применения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20370401

TG01 Patent term adjustment